Steven Nissen, M.D.

New Capabilities

Senior investigator on the CTX310 program

CRISPR Therapeutics' CTX310 cut triglycerides by 63% and ANGPTL3 by 65% a month after one infusion in 10 patients with severely high triglycerides, the company reported Nov. 9 at the American Heart Association meeting. The Phase 1b results follow a Phase 1a trial in which the same one-time treatment kept LDL cholesterol about 52% lower for a year.

Updated 2 days ago

New Capabilities

Presented the trial results and published them in the New England Journal of Medicine

For five years, 8,322 people who had already survived a heart attack or stroke injected either pelacarsen or a placebo every month. The drug did what it was designed to do: it cut lipoprotein(a), a cholesterol-carrying particle, by 78%. Major cardiovascular events occurred in 12.3% of the pelacarsen group and 12.1% of the placebo group.

Updated 4 days ago